KAS
VTGN icon

Kestra Advisory Services’s VistaGen Therapeutics VTGN Stock Holding History

Kestra Advisory Services’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.88K Hold
26,000
– – ﹤0.01% 3255
2026
Q1 		$14.9K Sell
26,000
-33
-0.1% -$20 ﹤0.01% 3099
2025
Q4 		$17.2K Buy
26,033
+6,000
+30% +$21.7K ﹤0.01% 4523
2025
Q3 		$71.1K Hold
20,033
– – ﹤0.01% 2843
2025
Q2 		$40.1K Hold
20,033
– – ﹤0.01% 2782
2025
Q1 		$50.1K Sell
20,033
-83
-0.4% -$235 ﹤0.01% 2648
2024
Q4 		$59.3K Buy
20,116
+83
+0.4% +$234 ﹤0.01% 2601
2024
Q3 		$60.3K Buy
+20,033
New +$68.4K ﹤0.01% 2498

Other funds holding VTGN

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CWS
Confluence Wealth Services Mcmurray, Pennsylvania $3.5B AUM 22.08% 1-Year Est. Return

Kestra Advisory Services's VTGN Position: Q2 2026 in Review

Kestra Advisory Services held its VistaGen Therapeutics (VTGN) position steady in Q2 2026 at 26,000 shares worth $5.88K. The position accounts for ﹤0.01% of the portfolio, ranked #3255.

Kestra Advisory Services first reported a position in VTGN in Q3 2024 and has held it in 8 quarters since. The position peaked at $71.1K in Q3 2025. 26 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Kestra Advisory Services held 26,000 shares of VistaGen Therapeutics worth $5.88K as of Q2 2026.
  • Kestra Advisory Services left its VistaGen Therapeutics share count unchanged in Q2 2026.
  • VistaGen Therapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q2 2026, its #3255 holding.
  • Kestra Advisory Services first reported a position in VistaGen Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Kestra Advisory Services's VistaGen Therapeutics position peaked at $71.1K in Q3 2025.
  • 26 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.